FINWIRES · TerminalLIVE
FINWIRES

德国DAX指数本周开盘走低;德国消费者信心进一步减弱

By

-- 德国股市周一开盘走低,蓝筹股DAX指数下跌0.19%,市场正等待本周内主要央行公布的利率决议。 美联储将于周三宣布最新货币政策决定,而欧洲央行和英国央行的决议将于周四公布。 在国内,德国消费者信心似乎进一步恶化。受收入下降和经济预期下滑的影响,GfK 2026年5月消费者信心指数从一个月前修正后的-28.1点降至-33.3点。该指数为2023年2月以来的最低水平,低于Investing.com预测的-30.2点。 “受伊朗战争引发的能源价格上涨影响,德国3月份通胀率从1.9%升至2.7%,导致大多数消费者再次预期物价上涨。尽管4月份价格预期指标的涨幅略低于3月份——这可能是由于加油站油价下跌所致——但与年初相比,该指标水平有所上升。”由GfK支持的NIM消费者信心指数调查显示。 与此同时,在高度地缘政治不确定性的背景下,德国出口前景略有改善,积极的预期大致抵消了消极的预期。ifo经济研究所的出口预期指标从上月的-0.7点升至4月份的0.1点。 在企业新闻方面,据彭博新闻社援引匿名消息人士报道,德国官员与欧洲各银行举行了非正式的初步会谈,探讨新的战略投资者收购或接管德国商业银行(CBK.F)股份的可能性。据称,持有德国商业银行12%股份的德国政府正在寻找替代方案,以取代意大利联合信贷银行(UniCredit)可能提出的收购要约。联合信贷银行于2026年初提交了收购要约。德国商业银行股价收盘上涨2.39%。

Related Articles

Insider Trading

Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing

Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml

$LFST
Australia

Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set

Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.

$CLS
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.

$AMP